RECRUITING

A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

Conditions

HIV Infections VH3810109 N6LS Broadly neutralizing antibody (bNAb)Fostemsavir (FTR)RUKOBIA INSTI-based ART Human Immunodeficiency Virus (HIV)HIV reservoir Adults living with HIV

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) regimen (Population 2).

Official Title

An Exploratory Phase 1b, Multicenter, Randomized, Open-Label Study to Investigate the Impact of the Administration of Intravenous VH3810109 With or Without Oral Fostemsavir in Combination With Integrase Inhibitor-Based Antiretroviral Therapy on the Viral Reservoir in Adults Living With HIV-1

Quick Facts

Study Start:2025-07-10

Study Completion:2028-03-24

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT07053384

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 70 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Age between 18 years and 70 years old at the time of obtaining informed consent. * Persons of any sex or gender are eligible. Note: Participants of childbearing potential (POCBP) are eligible to participate if not pregnant, not lactating, and agreeing to adhere to study requirements for use of contraception and pregnancy avoidance. * Participant has a documented diagnosis of HIV-1 infection Note: Participants in Population 1 must have a documented positive HIV antibody result available for Screening. * Plasma HIV-1 RNA \>=2000 copies/milliliter (c/mL) at Screening. * CD4+ T cell count \>=300 cells/microliter (μL) at Screening. * Antiretroviral treatment naïve, defined as no exposure to ART after a diagnosis of HIV-1 infection, prior to enrollment. * Participant is stably virologically suppressed (plasma HIV-1 RNA \<50 c/mL). * Documented evidence of uninterrupted treatment with oral non-boosted INSTI-based ART for at least 6 months prior to Screening, as well as uninterrupted treatment with ART (any guideline-recommended oral regimen) for at least 24 months prior to Screening. * CD4+ T cell count \>=450 cells/μL at Screening. * Body weight \>=50 kg to \<=115 kg. * Participant is capable of giving written informed consent, which includes adherence to the requirements and restrictions listed in the consent form and in the protocol.	* Participant is pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study. * Participant has documented diagnosis of HIV-2 infection. * Participant is known to have acquired HIV via perinatal transmission. * Any evidence of a current or known past Center for Disease Control and Prevention (CDC) Stage 3 disease. * Any ongoing malignancy or history of systemic cancers, such as Kaposi's sarcoma and lymphoma, or other virus-associated malignancies. * Ongoing or clinically relevant pancreatitis. * Current HIV-related kidney disease. * History of or active HIV-associated dementia or progressive multifocal leukoencephalopathy. * Ongoing or any lifetime history of clinically significant cardiovascular or cardiac disease. * Confirmed QTcF value outside normal range at Screening or Day 1. * Participants with severe hepatic impairment. * Advanced MAFLD and advanced non-alcoholic steatohepatitis, if evidence for substantial fibrosis (fibrosis score ≥F2) or evidence of cirrhosis. * Unstable liver disease. * History of liver cirrhosis with or without hepatitis viral co-infection. * Participants who are experiencing (Population 1) or are known to have initiated ART during (Population 2) acute HIV infection. * Any verified Grade 4 laboratory abnormality at Screening, excluding asymptomatic elevations of lipids or CPK. * Alanine transferase (ALT) \>=3 times the upper limit of normal (ULN) at Screening. * Estimated glomerular filtration rate (eGFR) of \<60 mL/min/1.73 m\^2. * Hemoglobin \>=Grade 2 at Screening. * Platelets \>=Grade 2 at Screening. * Absolute Neutrophil Count (ANC) ≥Grade 2 at Screening. * Any acute abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's inclusion in an interventional clinical study. * Active hepatitis B virus (HBV) co-infection. * Active hepatitis C virus (HCV) co-infection. * Participant has untreated syphilis before enrolment. * Known current untreated or incompletely treated active Mycobacterium TB infection. * Prior use of any of the following agents: * HIV-1 immunotherapeutic vaccines or prophylactic vaccines (any lifetime use) * HIV-1 monoclonal antibody therapy (any lifetime use). * Prior receipt of any approved or experimental non-HIV vaccination within 2 weeks prior to study enrolment. * History of systemic corticosteroids, immunosuppressive anti-cancer, interleukins, systemic interferons, or systemic chemotherapy, within 6 months prior to Screening. * Participant has received an experimental drug or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent (whichever is longer), prior to enrolment. * Treatment with any of the following agents within 30 days of enrolment: * anti-tuberculosis therapy * immunomodulators that alter immune responses such as chronic systemic corticosteroids, interleukins, or interferons. * Participant is receiving any protocol-defined prohibited medication and is unwilling or unable to switch to an alternate medication. Prohibited medications must be stopped within 7 days (or 14 days if the drug is a potential CYP3A4 enzyme inducer) or 5 half-lives (whichever is longer), prior to enrolment. * History or presence of allergy or intolerance to the study drugs or their components or drugs of their class, or a history of drug or other allergy that contraindicates study participation. * Any condition which may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive study drugs. * Any pre-existing physical or mental condition (including substance use disorder) which, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant. * Participant is currently participating in, or anticipates being selected for, any other interventional study.

Inclusion Criteria

Exclusion Criteria

* Age between 18 years and 70 years old at the time of obtaining informed consent.
* Persons of any sex or gender are eligible. Note: Participants of childbearing potential (POCBP) are eligible to participate if not pregnant, not lactating, and agreeing to adhere to study requirements for use of contraception and pregnancy avoidance.
* Participant has a documented diagnosis of HIV-1 infection Note: Participants in Population 1 must have a documented positive HIV antibody result available for Screening.
* Plasma HIV-1 RNA \>=2000 copies/milliliter (c/mL) at Screening.
* CD4+ T cell count \>=300 cells/microliter (μL) at Screening.
* Antiretroviral treatment naïve, defined as no exposure to ART after a diagnosis of HIV-1 infection, prior to enrollment.
* Participant is stably virologically suppressed (plasma HIV-1 RNA \<50 c/mL).
* Documented evidence of uninterrupted treatment with oral non-boosted INSTI-based ART for at least 6 months prior to Screening, as well as uninterrupted treatment with ART (any guideline-recommended oral regimen) for at least 24 months prior to Screening.
* CD4+ T cell count \>=450 cells/μL at Screening.
* Body weight \>=50 kg to \<=115 kg.
* Participant is capable of giving written informed consent, which includes adherence to the requirements and restrictions listed in the consent form and in the protocol.

* Participant is pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study.
* Participant has documented diagnosis of HIV-2 infection.
* Participant is known to have acquired HIV via perinatal transmission.
* Any evidence of a current or known past Center for Disease Control and Prevention (CDC) Stage 3 disease.
* Any ongoing malignancy or history of systemic cancers, such as Kaposi's sarcoma and lymphoma, or other virus-associated malignancies.
* Ongoing or clinically relevant pancreatitis.
* Current HIV-related kidney disease.
* History of or active HIV-associated dementia or progressive multifocal leukoencephalopathy.
* Ongoing or any lifetime history of clinically significant cardiovascular or cardiac disease.
* Confirmed QTcF value outside normal range at Screening or Day 1.
* Participants with severe hepatic impairment.
* Advanced MAFLD and advanced non-alcoholic steatohepatitis, if evidence for substantial fibrosis (fibrosis score ≥F2) or evidence of cirrhosis.
* Unstable liver disease.
* History of liver cirrhosis with or without hepatitis viral co-infection.
* Participants who are experiencing (Population 1) or are known to have initiated ART during (Population 2) acute HIV infection.
* Any verified Grade 4 laboratory abnormality at Screening, excluding asymptomatic elevations of lipids or CPK.
* Alanine transferase (ALT) \>=3 times the upper limit of normal (ULN) at Screening.
* Estimated glomerular filtration rate (eGFR) of \<60 mL/min/1.73 m\^2.
* Hemoglobin \>=Grade 2 at Screening.
* Platelets \>=Grade 2 at Screening.
* Absolute Neutrophil Count (ANC) ≥Grade 2 at Screening.
* Any acute abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's inclusion in an interventional clinical study.
* Active hepatitis B virus (HBV) co-infection.
* Active hepatitis C virus (HCV) co-infection.
* Participant has untreated syphilis before enrolment.
* Known current untreated or incompletely treated active Mycobacterium TB infection.
* Prior use of any of the following agents:
* HIV-1 immunotherapeutic vaccines or prophylactic vaccines (any lifetime use)
* HIV-1 monoclonal antibody therapy (any lifetime use).
* Prior receipt of any approved or experimental non-HIV vaccination within 2 weeks prior to study enrolment.
* History of systemic corticosteroids, immunosuppressive anti-cancer, interleukins, systemic interferons, or systemic chemotherapy, within 6 months prior to Screening.
* Participant has received an experimental drug or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent (whichever is longer), prior to enrolment.
* Treatment with any of the following agents within 30 days of enrolment:
* anti-tuberculosis therapy
* immunomodulators that alter immune responses such as chronic systemic corticosteroids, interleukins, or interferons.
* Participant is receiving any protocol-defined prohibited medication and is unwilling or unable to switch to an alternate medication. Prohibited medications must be stopped within 7 days (or 14 days if the drug is a potential CYP3A4 enzyme inducer) or 5 half-lives (whichever is longer), prior to enrolment.
* History or presence of allergy or intolerance to the study drugs or their components or drugs of their class, or a history of drug or other allergy that contraindicates study participation.
* Any condition which may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive study drugs.
* Any pre-existing physical or mental condition (including substance use disorder) which, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
* Participant is currently participating in, or anticipates being selected for, any other interventional study.

Contacts and Locations

Study Contact

US GSK Clinical Trials Call Center

CONTACT

877-379-3718

GSKClinicalSupportHD@gsk.com

EU GSK Clinical Trials Call Center

CONTACT

+44 (0) 20 89904466

GSKClinicalSupportHD@gsk.com

Study Locations (Sites)

GSK Investigational Site

Fort Pierce, Florida, 34982

United States

GSK Investigational Site

Kansas City, Missouri, 64111

United States

Collaborators and Investigators

Sponsor: ViiV Healthcare

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-07-10

Study Completion Date2028-03-24

Study Record Updates

Study Start Date2025-07-10

Study Completion Date2028-03-24

Terms related to this study

Keywords Provided by Researchers

VH3810109
N6LS
Broadly neutralizing antibody (bNAb)
Fostemsavir (FTR)
RUKOBIA
INSTI-based ART
Human Immunodeficiency Virus (HIV)
HIV reservoir
Adults living with HIV

Additional Relevant MeSH Terms

HIV Infections